Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: Treatment update

Current Opinion in Neurology

Volumn 23, Issue 5, 2010, Pages 519-523

  Nobile Orazio, Eduardo ^a   Gallia, Francesca ^a   Tuccillo, Francesco ^a   Terenghi, Fabrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

chronic inflammatory demyelinating polyradiculoneuropathy; interferon; intravenous immunoglobulin; methotrexate; multifocal motor neuropathy; mycophenolate mofetil

Indexed keywords

BETA INTERFERON; BETA INTERFERON 1A; DEXAMETHASONE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTANOIC ACID; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG;

CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; PLASMAPHERESIS; POLYRADICULONEUROPATHY; REVIEW;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956393520     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833dd218     Document Type: Review

References (50)

1. Hughes RAC, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006; 11:30-46.
2. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005; 31:663-680.
3. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; 1: CD001797.
4. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005; 2: CD004429.
5. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; 1: CD002062.
6. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; 3: CD003906.
7. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; 4: CD003280.
8. Umapathi T, Hughes R, Nobile-Orazio E, Leger J. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2009; 1: CD003217.
9. Kusumi M, Nakashima K, Nakayama H, et al. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tattori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49:169-174.
10. Laughlin RS, Dyck PJ, Melton LJ, et al. Incidence and prevalence of CIDP and the associations with diabetes mellitus. Neurology 2009; 73:39-45.
11. Rajabally YA, Simpson BJ, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of UK population. Muscle Nerve 2009; 39:432-438.
12. Lunn MPT, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66:677-680.
13. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010; 15:1-9.
14. Donofrio PD, Berger A, Brannagan TH3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009; 40:890-900.
15. Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17:289-294.
16. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15:50-56.
17. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind randomised controlled trial. Lancet Neurol 2010; 9:245-253.
18. Muley SA, Kelkar P, Parr GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008; 65:1460-1464.
19. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62:249-254.
20. Molenaar DSM, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1997; 62:388-390.
21. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebocontrolled trial. Lancet Neurol 2008; 7:136-144.
22. Merkies IS, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements in CIDP with immunoglobulin IV 10%: the ICE study. Neurology 2009; 72:1337-1344.
23. Nobile-Orazio E. Evidence for long-term IVIg treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Nature Clin Pract Neurology 2008; 4:352-353.
24. Lee D-Y, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008; 37:406-409.
25. Dyck PJ, O;Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1995; 35:1173-1176.
26. Hadden RDM, Sharrack B, Bensa S, et al. Randomized trial of interferon b-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53:57-61.
27. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC Trial): a pilot, multicentre study. Lancet Neurol 2009; 8:158-164
28. Hughes RAC, Gorson KC, Cros D, et al. Intramusculatr interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74:651-657.
29. Marsh EA, Hirst CL, Llewelyn JC, et al. Alentuzumab in the treatment of IVIgdependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257:913-919.
30. Mahdi-Rogers M, Kazmi M, Ferner R, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst 2009; 14:118-124.
31. Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010; 81:634-636.
32. Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neuro 2002; l9:683-685.
33. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004; 63:715-717.
34. Benedetti L, Briani C, Fazio R, et al. Rituximab in patients with CIDP: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2010 [Epub ahead of print].
35. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35:66-69.
36. Lievens I, Fournier E, Viala K, et al. [Multifocal motor neuropathy: a retrospective study of sensory nerve conduction velocities in long-termfollow-up of 21 patients.] (Article in French). Rev Neurol 2009; 165:243-248.
37. Delmont E, Benam C, Launay M, et al. Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition? J Neurol 2009; 256:1876-1880.
38. Lambrecq V, Krim E, Rouanet-Larrivie; re M, Lagueny A. Sensory loss in multifocal motr neuropathy: a clinical and electrophysiological study. Muscle Nerve 1009; 39:131-136.
39. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006; 11:1-8.
40. Lehman HC, Hoffmann FR, Fusshoeller A, et al. The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 2008; 271:34-39.
41. Lé ger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 2008; 79:93-96.
42. Bauman A, Hess CW, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 2009; 256:608-614.
43. Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009; 14:93-100.
44. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single -blinded cross-over trial. Eur J Neurol 2009; 16:631-638.
45. Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 2007; 130:2004-2010.
46. Nobile-Orazio E, Terenghi F, Cocito D, et al. Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst 2009; 14:203-205.
47. Radziwill AJ, Botez S, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. J Peripher Nerv Syst 2009; 14:201-202.
48. Axelson HW, Oberg G, Askmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand 2008; 117:432-434.
49. Stieglbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromusc Disord 2009; 19:473-475.
50. Chaudhry V, Cornblath DR. An open label trial of rituximab (Rituxan1) in multifocal motor neuropathy. J Peripher Nerv Syst 2010; (in press).